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Irritable bowel syndrome (IBS) is a common chronic gastrointestinal disorder that is characterized by intermittent
abdominal pain/discomfort, altered bowel habits and abdominal bloating/distension. This review aimed at
presenting the recent developments concerning the role of diet in the pathophysiology and management of IBS.
There is no convincing evidence that IBS patients suffer from food allergy/intolerance, and there is no evidence
that gluten causes the debated new diagnosis of non-coeliac gluten sensitivity (NCGS). The component in wheat
that triggers symptoms in NCGS appears to be the carbohydrates. Patients with NCGS appear to be IBS patients
who are self-diagnosed and self-treated with a gluten-free diet. IBS symptoms are triggered by the consumption of
the poorly absorbed fermentable oligo-, di-, monosaccharides and polyols (FODMAPs) and insoluble fibre. On
reaching the distal small intestine and colon, FODMAPS and insoluble fibre increase the osmotic pressure in the
large-intestine lumen and provide a substrate for bacterial fermentation, with consequent gas production,
abdominal distension and abdominal pain or discomfort. Poor FODMAPS and insoluble fibres diet reduces the
symptom and improve the quality of life in IBS patients. Moreover, it changes favourably the intestinal microbiota
and restores the abnormalities in the gastrointestinal endocrine cells. Five gastrointestinal endocrine cell types that
produce hormones regulating appetite and food intake are abnormal in IBS patients. Based on these hormonal
abnormalities, one would expect that IBS patients to have increased food intake and body weight gain. However,
the link between obesity and IBS is not fully studied. Individual dietary guidance for intake of poor FODMAPs and
insoluble fibres diet in combination with probiotics intake and regular exercise is to be recommended for IBS
patients.
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Irritable bowel syndrome (IBS) is a common chronic
gastrointestinal disorder that affects 5–20% of the gen-
eral population [1-15]. IBS is usually diagnosed at a
young age (i.e. <50 years of age) and is more common in
females than males [1,3,5,6,16]. This condition reduces
considerably the patients’ quality of life, although it is
not known to progress to a more serious disease or to
cause death [1,17-19].
IBS patients suffer from intermittent abdominal pain/
discomfort, altered bowel habits and abdominal bloat-
ing/distension [1,2]. Patients believe that their symptoms
are triggered by certain food items such as milk and
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article, unless otherwise stated.peas, beans, hot spices, and fried and smoked food
[20-23]. Some IBS patients avoiding several foodstuffs,
but there does not appear to be any difference between
them and the general population regarding the intake of
energy, carbohydrates, proteins and fats [23-29]. How-
ever, one study found that 62% of IBS patients had either
limited or excluded certain food items from their daily
diet, and of these 12% were at risk of long-term nutri-
tional deficiencies [30].
The role of diet in the development of IBS symptoms
and dietary management as a tool for controlling these
symptoms has been the subject of several reviews
[20,29,31-36]. The aim of this review was to present the
recent developments concerning the role of diet in the
pathophysiology and management of IBS.Diet and the pathophysiology of IBS
It is generally accepted that diet plays an important role
in the pathophysiology of IBS [27,36-45]. Several factorsed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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IBS, such as food allergy/intolerance, poorly absorbed
carbohydrates and fibre, and the comorbidity of obesity
and IBS.
Food allergy/intolerance
Food allergy occurs in 6–8% of children and 1–4% of
adults [46]. The food allergy reaction, which is mediated
by immunoglobulin E, occurs within 2 hours of ingesting
the offending food item, and manifests as swelling, itch-
ing, hives, wheezing, nausea, vomiting, diarrhoea, ab-
dominal pain and collapse. There is no evidence that
such an allergic reaction takes place in IBS [47-54]. A
large proportion of IBS patients complain of subjective
intolerance to various foods [20,21,52,55-60]. Food in-
tolerance is a non-toxic, non-immune-mediated reaction
to bioactive chemicals in food such as histamines, sul-
phites and monosodium glutamate, with symptoms
usually manifesting outside the gastrointestinal tract.
There is no documented proof that such intolerance
occurs in IBS [42,54].
Non-coeliac gluten sensitivity (NCGS) has recently re-
ceived attention from the mass media and the general
public, and has become confused with the popular
speculation that the high carbohydrate content of wheat
is responsible for negative health aspects such as obesity
[61]. NCGS is defined as having gastrointestinal and
extra-gastrointestinal IBS-like symptoms without coeliac
disease or wheat allergy, but with the symptoms being
relieved by a gluten-free diet (GFD) and relapsing on
gluten challenge [62-69]. The prevalence of NCGS has
been reported as 0.55–6% of the USA population
[64,70].
For more than 3 decades, patients with abdominal
pain, diarrhoea and small-intestine biopsy findings with
no significant changes have experienced symptom relief
on a GFD with return of the symptoms after a gluten
challenge [71,72]. Similar results have been reported in
patients with non-celiac IBS-like symptoms [73-75]. This
was confirmed by double-blind randomized placebo-
controlled studies [76,77]. There is disagreement as to
whether or not NCGS patients have low-grade inflam-
mation and abnormal intestinal permeability [74,77-82].
It is noteworthy that in studies showing beneficial
effects on symptoms in NCGS [74,76,77], those effects
were actually the result of wheat withdrawal rather than
withdrawal of gluten [83]. In a placebo-controlled, cross-
over study of patients with IBS-like symptoms on a self-
imposed GFD [84], the gastrointestinal symptoms con-
sistently and significantly improved when consuming a
diet with reduced fermentable oligo-, di-, monosaccha-
rides and polyols (FODMAPs), and these symptoms were
not worsened by either a low- or high-dose challenge
with gluten. It therefore seems that the carbohydratecontent (fructans and galactans) of wheat rather than
gluten is responsible for triggering NCGS symptoms.
Furthermore, in those who believed that they had
NCGS, 24% had uncontrolled symptoms despite con-
suming a GFD, 27% did not follow a GFD alone, and
65% avoided other foods that contain high levels of
FODMAPs [85]. These findings lend further support to
the idea that NCGS symptoms are not triggered by the
gluten in wheat.
The basic description of NCGS [67] is the same as that
of IBS. Both NCGS and IBS patients have the same gastro-
intestinal and extra-gastrointestinal symptoms that are
triggered by wheat consumption. NCGS patients have
been reported to have high frequency of immunoglobulin
G (IgG)/immunoglobulin A (IgA) antigliadin antibodies
(AGA) and a stronger association with human leucocyte
antigen-DQ2 (DQ2) and -DQ8 (DQ8) [76]. The preva-
lence of positivity for IgG/IgA AGA, with negative
tissue transglutaminase or deamidated gliadin peptide
antibodies, in the blood of IBS patients has been re-
ported to be 5–17% [86-88] or as high as about 50%
[65,89]. Serum AGA has been reported to have a good
sensitivity but a low specificity for coeliac disease [90],
and 12–15% of serum samples from healthy subjects are
positive for AGA [86,87,90,91]. Moreover, DQ2 and
DQ8 are common in the general population. It appears
that NCGS patients are IBS patients with a self-diagnosis
and who self-treat with a GFD. It is noteworthy in this
context that 20–70% of IBS patients complain of subject-
ive intolerance to various foods [20,21,52,55-60].
Poorly absorbed carbohydrates and fibre
The triggering of symptoms in IBS patients by certain
foodstuff has been attributed to indigestible and poorly
absorbed short-chain carbohydrates, FODMAPs [42,92-94]
and FODMAPs intake is hypothesized to be one factor
among others for IBS aetiology. These short-chain sugars
include fructose, lactose, sugar alcohols (sorbitol, maltitol,
mannitol, xylitol and isomalt), fructans and galactans [42].
FODMAPs occur in a wide range of foods, including
wheat, rye, vegetables, fruits and legumes [95-97]. A signifi-
cant proportion of these carbohydrates enter the distal
small intestine and colon, where they exert osmotic effects
in the large-intestine lumen, increasing its water content
and providing a substrate for bacterial fermentation, with
consequent gas production [92,95,98]. The produced gas
causes abdominal distension and abdominal pain/dis-
comfort. FODMAPs have been found to trigger gastro-
intestinal symptoms in IBS, and a low-FODMAPs diet
reduces the symptoms and improves the patient’s qual-
ity of life [23,29,93,94,99-102]. Recent studies have shown
that the mechanisms by which FODMAPs exert their
effects are more complicated than originally thought. A
low-FODMAPs diet appears to induce favourable changes
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endocrine cells [104-107].
It has been reported that changing from typical
Australian food to a low-FODMAPs diet changed the in-
testinal microbiota [103]. Thus, a low-FODMAPs diet in
healthy subjects and IBS patients reduced the total bac-
terial abundance, while a typical Australian diet increased
the relative abundance of butyrate-producing Clostridiun
cluster XIVa and the mucus-associated Akkermansia
muciniphia, and reduced Ruminococcus torques [103].
Several types of endocrine cell in all segments of
the gastrointestinal tract of IBS patients are abnormal
[108-129]. The gastrointestinal endocrine cells interact
and integrate with each other, with the enteric ner-
vous system and with the afferent and efferent nerve
fibres of the central nervous system, in particular the
autonomic nervous system [42,130-132]. These cells
regulate several functions of the gastrointestinal tract,
including sensation, motility, secretion, absorption, local
immune defence and food intake (by affecting appetite)
[42,131-134]. The abnormalities in the gastrointestinal
endocrine cells are considered to play a major role in
the development of symptoms in IBS, and therefore rep-
resent future targets for treatment [43,135]. Switching
from a typical Norwegian diet to a low-FODMAPs diet
was shown to lead to normalization of the endocrine
cells in the stomach and large intestines [104-107].
A low intake of dietary fibre was initially believed to
be the cause of IBS [136]. In clinical settings the increase
in dietary fibre intake in IBS patients has been found to
increase abdominal pain, bloating and abdominal disten-
sion. A meta-analysis of 12 trials revealed that IBS
patients treated with increased fibre intake had no im-
provement in symptoms compared to placebo or a low-





Stomach Ghrelin Increased Un
Serotonin Increased Un
Duodenum CCK Decreased Un
Serotonin Unchanged Un
Ileum PYY Unchanged Un
Serotonin Decreased De
Colon PYY Decreased Un
Serotonin Decreased Un
Rectum PYY Decreased De
Enteroglucagon Decreased Un
Serotonin Unchanged Un
IBS-D, IBS patients with diarrhoea as the predominant symptom; IBS-M, IBS patients
constipation as the predominant symptom.water-soluble fibre—but not insoluble fibre—improves
the symptoms [138,139].Obesity and IBS
As mentioned above, IBS patients tend to avoid certain
food items that they associate with the onset of their
symptoms. There has been some concern that the onset
of IBS symptoms upon ingesting certain foods would re-
duce the amount of food consumed and thereby lead to
malnutrition [30]. However, whereas an association be-
tween low BMI and IBS in 367 patients with IBS has
been reported [140], in another report most of the 330
IBS patients examined were either normal or over-
weight [20]. In a recent comprehensive review, the asso-
ciation between IBS and obesity was found to be
controversial, and the author concluded that obesity
and IBS might be linked [141].
Appetite is regulated by a large number of hormones,
several of which are secreted by gastrointestinal endo-
crine cells [142]. The gastrointestinal hormones exert
their effects by acting upon the appetite control centre
in the hypothalamus [142]. The arcuate nucleus (ARC)
lies in the median eminence, which lacks a complete
blood barrier, making the ARC particularly susceptible
to hormones circulating in the blood [142-145]. The
ARC is the centre that integrates the neurological and
blood-borne signals [142-145]. The brain reward system
in the midbrain controls hedonic feeding (i.e. the con-
sumption of palatable food), which is modulated by
blood-borne signals [145].
The following five gastrointestinal endocrine cell types
that secrete hormones that regulate appetite are abnor-
mal in patients with IBS: ghrelin, cholecystokinin (CCK),
peptide YY (PYY), enteroglucagon (oxyntomodulin) andthat regulate appetite in IBS patients
Hormone function
-M IBS-C
changed Decreased Orexigenic (increases appetite)
changed Decreased Anorexigenic (decreases appetite)
changed Unchanged Anorexigenic (decreases appetite)
changed Unchanged See above
changed Increased Anorexigenic (decreases appetite)
creased Decreased See above
known Decreased See above
known Decreased See above
creased Decreased See above
known Decreased Anorexigenic (decreases appetite)
known Unchanged See above
with alternating diarrhea and constipation; IBS-C, IBS patients with
Figure 1 Ghrelin-immunoreactive cells in the oxyntic mucosa of a healthy subject (A), in a patient with IBS-D (B) and in a patient with IBS-C (C).
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[108-110,112-115,132,146-149]. The endocrine cells in
the oxyntic mucosa are the main source of circulating
ghrelin, although small amounts do occur in the small
and large intestines as well as in the ARC of the hypo-
thalamus [144,150-153]. Ghrelin has several roles, such
as regulating the release of pituitary growth hormone
and accelerating gastric and intestinal motility [150-166].
Moreover, ghrelin increases appetite and feeding; cen-
tral or peripheral administration of ghrelin stimulates
the consumption of food and body weight gain [150].
CCK stimulates gallbladder contraction, intestinal mo-
tility and pancreatic exocrine secretion, and inhibits
gastric motility and food consumption [131]. The an-
orexigenic action of CCK occurs via the CCK-B (CCK-
2) receptor, which is the predominant receptor type in
the brain [167-183]. PYY release is proportional to the
composition (including calorie content) of a particular
meal, and its infusion reduces the consumption of foodFigure 2 Duodenal CCK cells in a healthy subject (A) and in a patient with[184,185]. PYY binds to Y2 receptors localized on the
presynaptic terminals of neuropeptide Y and to agouti-
related protein neurons in the hypothalamus, which
causes inactivation of these neurons, resulting in an-
orexia [186]. Moreover, PYY is the main regulator of the
ileal brake and consequently inhibits the consumption of
further food once nutrients reach the terminal ileum
[187-194]. Enteroglucagon reduces gastric motility and
secretion [195-200] and, similar to PYY, the amount
released into the bloodstream is proportional to the calo-
ries ingested [201,202]; however, enteroglucagon seems
to have only a modest anorexigenic effect [145]. Sero-
tonin has also been reported to have an anorexigenic
effect [203].
Whereas the ghrelin cell density is increased in IBS
patients with diarrhoea as the predominant symptom
(IBS-D), it is reduced in IBS patients with constipation
as the predominant symptom (IBS-C). It is therefore
reasonable to assume that IBS-D patients would have aIBS (B).
Figure 3 PYY cells in the colon of a healthy subject (A) and in a patient with IBS (B).
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In both IBS subtypes, the densities of the four endocrine
cell types that produce anorexigenic hormones—namely
CCK, PYY, enteroglucagon and serotonin—are reduced.
Thus, the changes in the gastrointestinal endocrine cells
regulating appetite in IBS patients favour an increase in
food consumption. BMI and appetite in IBS patients
have not been studied in detail, and the available data
are controversial. It is not clear whether IBS patients
have a greater appetite, which is opposed by the avoid-
ance of eating because of worsening of symptoms upon
eating. Further studies are needed to clarify this issue.
Diet and management of IBS
As mentioned above, it is recommended that IBS
patients consume a diet that is poor in FODMAPs and
insoluble fibre. IBS patients make a conscious choice to
avoid certain food items, some of which are rich in
FODMAPs, but they may also consume large amounts
of other food items that are rich in FODMAPs and avoid
food sources that are important to health maintenance
[23]. Dietary guidance is therefore important for IBS
patients [23,99]. Furthermore, in our experience individ-
ual dietary guidance is preferable due to the wide variety
of individual tolerances to different FODMAPs-rich food
items, probably due to the intestinal microbiota differing
between individuals.Figure 4 Rectal enteroglucagon cells in a healthy subject (A) and in a patiConsuming probiotics increases the tolerance for
FODMAPs-rich foodstuffs, and adding regular exercise
amplifies the beneficial effects of such a diet [1,204].
People in numerous countries (including Norway) rely
on bread and wheat products for a substantial part of
their diet [205]. Gluten-free bread (mostly made of rice/
corn) contains 0.19 g/100 g fructans, and bread made
with spelt flour contains 0.14 g/100 g [96]. Either gluten-
free products or spelt products can be consumed. Many
of our patients consume spelt bread and spelt products ra-
ther than gluten-free products, with satisfactory results.
The protein content of spelt flour is also 16% lower in
terms of gluten than that in wheat [206].Conclusion
Diet plays a major role in the pathophysiology of IBS
and is a powerful tool for managing IBS. There is no
convincing evidence that IBS patients suffer from food
allergy/intolerance, and there is evidence that NCGS is
caused by the fructans in wheat, rather than by gluten.
NCGS patients appear to be IBS patients who have self-
diagnosed and self-treated with a GFD. Food items that
are rich in poorly absorbed short-chain carbohydrates
(FODMAPs) and insoluble fibre trigger IBS symptoms.
There appear to be several mechanisms by which these
food items exert this effect (Figure 6):ent with IBS (B).
Figure 5 Serotonin cells in the colon of a healthy subject (A) and in a patient with IBS (B).
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they increase the osmotic pressure and provide a
substrate for bacterial fermentation, resulting in gas
production, abdominal distension and abdominal
pain/discomfort.
2. They are prebiotics that favour the colonization of
the large intestine with Clostridium bacteria, which
produce gas on fermentation.Figure 6 Schematic illustration for the possible mechanisms by which FOD
FODMAPs can exert direct or indirect effect on the intestinal endocrine cel
fermented by the intestinal microbiota with gas production. The productio
serotonin from serotonin (EC) cells. Serotonin act on the intrinsic sensory n
turn convey the activation to the extrinsic sensory nerve fibres (ESNF) to th3. They affect the gastrointestinal endocrine cells that
regulate gastrointestinal sensation, motility, secretion
and absorption, as well as local immune defence and
food consumption.
The link between obesity and IBS is an interesting area
that needs to be explored further. This is of particular
interest since IBS patients have an increased density ofMAPs can trigger IBS symptoms. Upon reaching the large intestine
ls. They act as prebiotics and change the intestinal flora and they are
n of gas increases the luminal pressure and stimulates the release of
erve fibres (ISNF) of the submucosal and myenteric ganglia, which in
e central nervous system.
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consumption of food and body weight gain, and have de-
creased densities of the four endocrine cells that produce
anorexigenic hormones, namely CCK, PYY, enterogluca-
gon and serotonin.
A diet that is poor in FODMAPs and insoluble fibre
reduces the symptoms and improves the quality of life of
IBS patients. Individual dietary guidance is necessary to
identify a suitable diet to which the patient is likely to
adhere to in the long term. Combining this diet with
probiotics and regular exercise will amplify the effect of
such a diet.
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